FDA issues genome-editing guidance
The FDA released draft guidance focused on best practices for genome‑editing gene therapies, with an emphasis on sequencing-based safety checks and risk reduction. The guidance highlights the growing role of next‑generation sequencing in assessing off-target effects and shaping clinical and manufacturing protocols. (clinicaltrialsarena.com) (cgtlive.com)
The Food and Drug Administration this week proposed a new playbook for checking the safety of genome-editing gene therapies before they reach human trials. (fda.gov) The draft guidance, issued April 14, 2026 by the Center for Biologics Evaluation and Research, tells drug sponsors how to use next-generation sequencing to look for edits that land in the wrong place and for broader damage to chromosomes. (fda.gov) Next-generation sequencing is a high-speed way to read DNA, like scanning a manuscript for typos after an editor makes targeted changes. The Food and Drug Administration said those sequencing methods will likely be needed in nonclinical studies submitted with investigational new drug applications and biologics license applications. (fda.gov) (govinfo.gov) Genome editing aims to rewrite a disease-causing stretch of DNA inside a patient’s cells. The agency’s new draft covers both ex vivo therapies, where cells are edited outside the body, and in vivo therapies, where the edit happens directly in tissue inside the body. (fda.gov) The document asks companies to standardize sequencing strategy, sample selection, analysis settings, and reporting. The Food and Drug Administration said the goal is a more complete readout of off-target editing and “loss of genome integrity,” its term for unintended structural changes in DNA. (fda.gov 1) (fda.gov 2) This is not the agency’s first genome-editing guidance. It builds on a January 2024 guidance that covered product design, manufacturing, nonclinical testing, clinical studies, and long-term follow-up for human gene therapies that incorporate genome editing. (fda.gov 1) (fda.gov 2) The timing lines up with a broader Food and Drug Administration push on individualized treatments for very small patient groups. In a February 23, 2026 announcement, the agency launched a draft framework for ultra-rare diseases aimed at sponsors that cannot run standard randomized trials because so few patients exist. (fda.gov) (hhs.gov) For companies developing one-off or small-batch gene therapies, that means the Food and Drug Administration is trying to tighten one part of the evidence package while loosening another. It is asking for more specific DNA-level safety checks even as it sketches alternative paths for products that may never be tested in large trials. (fda.gov 1) (fda.gov 2) The guidance is still a draft and is “not for implementation,” the agency said. Comments are due by July 14, 2026, after which the Food and Drug Administration will decide what to keep, revise, or finalize. (fda.gov) (govinfo.gov)
